Proactive Investors - Run By Investors For Investors

Genprex Inc retains pharmaceutical branding company to commercialize its lung cancer drug

the firm Addison Whitney will oversee the drug's naming process, which requires regulatory approval
Oncoprex name tag
The clinical-stage gene therapy company has developed a non-small cell lung cancer treatment, currently called Oncoprex

Genprex Inc (NASDAQ:GNPX) has moved one step closer to commercializing its flagship drug candidate Oncoprex by retaining pharmaceutical branding agency Addison Whitney.

The clinical-stage gene therapy company has developed the drug to treat non-small cell lung cancer treatment.

Addison Whitney will oversee the official naming process, which requires regulatory approval.

READ: Genprex reports positive preclinical data on its drug to treat lung cancer

"Retaining Addison Whitney is an important step in bringing our drug candidate to market,” Chairman and CEO Rodney Varner said. "Obtaining regulatory approval of proprietary and non-proprietary drug names is a necessary step in securing marketing approval, and Addison Whitney has an impressive track record in obtaining such name approvals.”

The Austin-based company’s drug fights non-small cell lung cancer by transporting cancer-fighting genes to cancerous cells.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

View full GNPX profile View Profile

Genprex, Inc. Timeline

Related Articles

skin
April 17 2019
Driving growth was Lojuxta, used to treat a rare and life-threatening disorder that causes abnormally high levels of bad cholesterol. Its sales grew to €13.6mln, up 14.2% year-on-year
Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
Enzymes under a microscope
April 28 2019
The Florida company applies its proprietary C1 gene expression platform to speed up the development of biologic vaccines, drugs at flexible commercial scales
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use